Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

30 Mar 2011

Abstract excerpt

The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21447828
DOI: 10.1182/blood-2011-02-297325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationPMID 21447828Read ↗

The future of autologous stem cell transplantation in myelomaSemantic proximity Read ↗

Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patientsSemantic proximity Read ↗

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersSemantic proximity Read ↗

The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?Semantic proximity Read ↗

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium.Semantic proximity Read ↗

Multiple myeloma.Semantic proximity Read ↗

Treatment outcome of newly diagnosed multiple myeloma patients: A retrospective analysis in a resource-limited settingSemantic proximity Read ↗

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or olderSemantic proximity Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

Biology and therapy of multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.